Abstract

Older adults with treatment‐resistant depression who received augmentation of their existing antidepressant with aripiprazole experienced significantly greater improvement in psychological well‐being than patients who were switched to bupropion, an open‐label trial has found. Fall rates also were lower in the aripiprazole augmentation group than among patients receiving bupropion augmentation or switching. Results were published online March 3, 2023, in The New England Journal of Medicine.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call